文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Global Research Trends in Tyrosine Kinase Inhibitors: Coword and Visualization Study.

作者信息

Hu Jiming, Xing Kai, Zhang Yan, Liu Miao, Wang Zhiwei

机构信息

School of Information Management, Wuhan University, Wuhan, China.

Department of Cardiovascular Surgery, Renmin Hospital of Wuhan University, Wuhan, China.

出版信息

JMIR Med Inform. 2022 Apr 8;10(4):e34548. doi: 10.2196/34548.


DOI:10.2196/34548
PMID:35072634
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9034433/
Abstract

BACKGROUND: Tyrosine kinase inhibitors (TKIs) have achieved revolutionary results in the treatment of a wide range of tumors, and many studies on this topic continue to be published every year. Some of the published reviews provide great value for us to understand TKIs. However, there is a lack of studies on the knowledge structure, bibliometric analysis, and visualization results in TKIs research. OBJECTIVE: This paper aims to investigate the knowledge structure, hotspots, and trends of evolution of the TKIs research by co-word analysis and literature visualization and help researchers in this field to gain a comprehensive understanding of the current status and trends. METHODS: We retrieved all academic papers about TKIs published between 2016 and 2020 from the Web of Science. By counting keywords from those papers, we generated the co-word networks by extracting the co-occurrence relationships between keywords, and then segmented communities to identify the subdirections of TKIs research by calculating the network metrics of the overall and local networks. We also mapped the association network topology, including the network within and between TKIs subdirections, to reveal the association and structure among varied subdirections. Furthermore, we detected keyword bursts by combining their burst weights and durations to reveal changes in the focus of TKIs research. Finally, evolution venation and strategic diagram were generated to reveal the trends of TKIs research. RESULTS: We obtained 6782 unique words (total frequency 26,175) from 5584 paper titles. Finally, 296 high-frequency words were selected with a threshold of 10 after discussion, the total frequency of which accounted for 65.41% (17,120/26,175). The analysis of burst disciplines revealed a variable number of burst words of TKIs research every year, especially in 2019 and 2020, such as HER2, pyrotinib, next-generation sequencing, immunotherapy, ALK-TKI, ALK rearrangement. By network calculation, the TKIs co-word network was divided into 6 communities: C1 (non-small-cell lung cancer), C2 (targeted therapy), C3 (chronic myeloid leukemia), C4 (HER2), C5 (pharmacokinetics), and C6 (ALK). The venation diagram revealed several clear and continuous evolution trends, such as non-small-cell lung cancer venation, chronic myeloid leukemia venation, renal cell carcinoma venation, chronic lymphocytic leukemia venation. In the strategic diagram, C1 (non-small-cell lung cancer) was the core direction located in the first quadrant, C2 (targeted therapy) was exactly at the junction of the first and fourth quadrants, which meant that C2 was developing; and C3 (chronic myeloid leukemia), C4 (HER2), and C5 (pharmacokinetics) were all immature and located in the third quadrant. CONCLUSIONS: Using co-word analysis and literature visualization, we revealed the hotspots, knowledge structure, and trends of evolution of TKIs research between 2016 and 2020. TKIs research mainly focused on targeted therapies against varied tumors, particularly against non-small-cell lung cancer. The attention on chronic myeloid leukemia and pharmacokinetics was gradually decreasing, but the focus on HER2 and ALK was rapidly increasing. TKIs research had shown a clear development path: TKIs research was disease focused and revolved around "gene targets/targeted drugs/resistance mechanisms." Our outcomes will provide sound and effective support to researchers, funders, policymakers, and clinicians.

摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ddd/9034433/35b4b756f88e/medinform_v10i4e34548_fig7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ddd/9034433/e1be3e36cae7/medinform_v10i4e34548_fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ddd/9034433/c16788e7aeb3/medinform_v10i4e34548_fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ddd/9034433/516f1a62e72c/medinform_v10i4e34548_fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ddd/9034433/cac40246cf52/medinform_v10i4e34548_fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ddd/9034433/978b090c6d3b/medinform_v10i4e34548_fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ddd/9034433/521c6b9bf2ff/medinform_v10i4e34548_fig6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ddd/9034433/35b4b756f88e/medinform_v10i4e34548_fig7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ddd/9034433/e1be3e36cae7/medinform_v10i4e34548_fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ddd/9034433/c16788e7aeb3/medinform_v10i4e34548_fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ddd/9034433/516f1a62e72c/medinform_v10i4e34548_fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ddd/9034433/cac40246cf52/medinform_v10i4e34548_fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ddd/9034433/978b090c6d3b/medinform_v10i4e34548_fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ddd/9034433/521c6b9bf2ff/medinform_v10i4e34548_fig6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ddd/9034433/35b4b756f88e/medinform_v10i4e34548_fig7.jpg

相似文献

[1]
Global Research Trends in Tyrosine Kinase Inhibitors: Coword and Visualization Study.

JMIR Med Inform. 2022-4-8

[2]
Intellectual Structure and Evolutionary Trends of Precision Medicine Research: Coword Analysis.

JMIR Med Inform. 2020-2-4

[3]
Determining the Intellectual Structure and Academic Trends of Smart Home Health Care Research: Coword and Topic Analyses.

J Med Internet Res. 2021-1-21

[4]
Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis.

BMC Cancer. 2020-4-16

[5]
Treatment Optimization for Brain Metastasis from Anaplastic Lymphoma Kinase Rearrangement Non-Small-Cell Lung Cancer.

Oncol Res Treat. 2019-9-17

[6]
Global research trends and hotspots of fecal microbiota transplantation: A bibliometric and visualization study.

Front Microbiol. 2022-8-18

[7]
Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.

Lancet Oncol. 2017-12

[8]
Treatment Sequencing in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer in Japan: A Real-World Observational Study.

Adv Ther. 2020-7

[9]
Research hotspots and trends in nursing education from 2014 to 2020: A co-word analysis based on keywords.

J Adv Nurs. 2022-3

[10]
Anaplastic Lymphoma Kinase Fusion: A Review of Therapeutic Drugs and Treatment Strategies.

Acta Med Okayama. 2020-10

引用本文的文献

[1]
The Status Quo of Pharmacogenomics of Tyrosine Kinase Inhibitors in Precision Oncology: A Bibliometric Analysis of the Literature.

Pharmaceutics. 2024-1-25

本文引用的文献

[1]
Therapeutic Sequencing in ALK NSCLC.

Pharmaceuticals (Basel). 2021-1-21

[2]
First-Line Lorlatinib or Crizotinib in Advanced -Positive Lung Cancer.

N Engl J Med. 2020-11-19

[3]
Ponatinib and other CML Tyrosine Kinase Inhibitors in Thrombosis.

Int J Mol Sci. 2020-9-8

[4]
Outcome of COVID-19 in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors.

J Oncol Pharm Pract. 2020-10

[5]
BTK/ITK dual inhibitors: Modulating immunopathology and lymphopenia for COVID-19 therapy.

J Leukoc Biol. 2021-1

[6]
Novel drugs targeting EGFR and HER2 exon 20 mutations in metastatic NSCLC.

Crit Rev Oncol Hematol. 2020-2-11

[7]
Intellectual Structure and Evolutionary Trends of Precision Medicine Research: Coword Analysis.

JMIR Med Inform. 2020-2-4

[8]
Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors.

J Clin Oncol. 2020-1-21

[9]
Publication Trends of Research on Sepsis and Host Immune Response during 1999-2019: A 20-year Bibliometric Analysis.

Int J Biol Sci. 2020-1-1

[10]
NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 1.2020.

J Natl Compr Canc Netw. 2019-12

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索